Entera Bio (ENTX) Income from Continuing Operations (2019 - 2026)
Entera Bio's (ENTX) quarterly Income from Continuing Operations came in at 3611000.0 in Q1 2026, down 37.88% YoY from 5812666.87 in Q1 2025, and down 15.07% on a QoQ basis from 3138000.0 in Q4 2025.
Entera Bio (ENTX) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Entera Bio (ENTX) has 8 years of Income from Continuing Operations data on file, last reported at 3611000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 37.88% year-over-year to 3611000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 12913000.0 (down 23.77% YoY) and the FY2025 annual result came in at 11439000.0, down 19.89% from the prior year.
- Income from Continuing Operations retreated to 3611000.0 in Q1 2026, from 3138000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1995000.0 in Q4 2023 to a low of 3784000.0 in Q1 2022.
- A 5-year average of 2786352.94 and a median of 2732000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 64.81% — and 2023, when it soared 42.12%.
- Tracing ENTX's Income from Continuing Operations over 5 years: stood at 3035000.0 in 2022, then surged by 34.27% to 1995000.0 in 2023, then retreated by 18.2% to 2358000.0 in 2024, then plunged by 33.08% to 3138000.0 in 2025, then declined by 15.07% to 3611000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 3611000.0 (Q1 2026), 3138000.0 (Q4 2025), and 3432000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Entera Bio | 161.44 Mn | 150.13 Mn | - | -4.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.58 Mn |
| Mar 31, 2026 | -3.61 Mn |
| Dec 31, 2025 | -3.14 Mn |
| Sep 30, 2025 | -3.43 Mn |
| Jun 30, 2025 | -2.73 Mn |
| Mar 31, 2025 | -2.62 Mn |
| Dec 31, 2024 | -2.36 Mn |
| Sep 30, 2024 | -3.02 Mn |
| Jun 30, 2024 | -2.44 Mn |
| Mar 31, 2024 | -2.06 Mn |
| Dec 31, 2023 | -2.00 Mn |
| Sep 30, 2023 | -2.38 Mn |
| Jun 30, 2023 | -2.33 Mn |
| Mar 31, 2023 | -2.19 Mn |
| Dec 31, 2022 | -3.04 Mn |
| Sep 30, 2022 | -3.07 Mn |
| Jun 30, 2022 | -3.19 Mn |
| Mar 31, 2022 | -3.78 Mn |
| Dec 31, 2021 | -4.10 Mn |
| Sep 30, 2021 | -3.21 Mn |